No. Your post presumes that the FDA is making its decisions strictly by the merits of a studies efficacy data when this is 100% NOT the case. So yes, without the same type of political pressure coming from NIH Gilead board members, UK could very well jump at something which has been not so quietly sitting on the FDAs perverbial desk.